ATE408418T1 - Methoden zur inhibition von hiv-assoziierten krankheiten mittels monoklonaler antikörper gegen sich selbstgerichtete zytotoxische t-zellen - Google Patents

Methoden zur inhibition von hiv-assoziierten krankheiten mittels monoklonaler antikörper gegen sich selbstgerichtete zytotoxische t-zellen

Info

Publication number
ATE408418T1
ATE408418T1 AT04101437T AT04101437T ATE408418T1 AT E408418 T1 ATE408418 T1 AT E408418T1 AT 04101437 T AT04101437 T AT 04101437T AT 04101437 T AT04101437 T AT 04101437T AT E408418 T1 ATE408418 T1 AT E408418T1
Authority
AT
Austria
Prior art keywords
hiv
monoclonal antibodies
inhibition
cells
methods
Prior art date
Application number
AT04101437T
Other languages
English (en)
Inventor
D Allen Allen
Original Assignee
D Allen Allen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by D Allen Allen filed Critical D Allen Allen
Application granted granted Critical
Publication of ATE408418T1 publication Critical patent/ATE408418T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04101437T 1993-03-19 1994-03-21 Methoden zur inhibition von hiv-assoziierten krankheiten mittels monoklonaler antikörper gegen sich selbstgerichtete zytotoxische t-zellen ATE408418T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3340593A 1993-03-19 1993-03-19
US16575193A 1993-12-13 1993-12-13
CA002425086A CA2425086A1 (en) 1993-03-19 2003-04-10 Method of increasing the delayed-type hypersensitivity response by infusing lfa-1 specific antibodies

Publications (1)

Publication Number Publication Date
ATE408418T1 true ATE408418T1 (de) 2008-10-15

Family

ID=34084057

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94912826T ATE267019T1 (de) 1993-03-19 1994-03-21 Methoden zur inhibition von hiv-assotiierte krankheit mittels monoklonaler antikörper gegen sich selbstgerichtete zytotoxische t-zellen
AT04101437T ATE408418T1 (de) 1993-03-19 1994-03-21 Methoden zur inhibition von hiv-assoziierten krankheiten mittels monoklonaler antikörper gegen sich selbstgerichtete zytotoxische t-zellen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT94912826T ATE267019T1 (de) 1993-03-19 1994-03-21 Methoden zur inhibition von hiv-assotiierte krankheit mittels monoklonaler antikörper gegen sich selbstgerichtete zytotoxische t-zellen

Country Status (10)

Country Link
US (1) US5424066A (de)
EP (2) EP1438970B1 (de)
AT (2) ATE267019T1 (de)
AU (1) AU684074B2 (de)
CA (2) CA2156495C (de)
DE (2) DE69435142D1 (de)
DK (1) DK1438970T3 (de)
ES (2) ES2219647T3 (de)
PT (2) PT690725E (de)
WO (1) WO1994021295A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5651970A (en) * 1993-03-19 1997-07-29 Allen; Allen D. Method for inhibiting disease associated with the human immunodeficiency virus through the use of monoclonal antibodies directed against anti-self cytotoxic T-lymphocytes or their lytics
US6534057B2 (en) 1993-03-19 2003-03-18 Allen D. Allen Method increasing the delayed-type hypersensitivity response by infusing LFA-1-specific antibodies
WO1995028176A1 (en) * 1994-04-15 1995-10-26 Allen Allen D Method of treating hiv infection using antibodies against cytotoxic t-cells and thymic humoral factor
AU720126B2 (en) * 1995-04-14 2000-05-25 Kabushiki Kaisha Tokyo Kagaku Kenkyusho Phosphor with afterglow characteristic
AU6256796A (en) * 1995-06-06 1996-12-24 D. Allen Allen Method for treating molluscum contagiosum resulting from hiv infection
WO1996040215A1 (en) * 1995-06-07 1996-12-19 Connective Therapeutics, Inc. Treating immune deficiency diseases using t cell receptor peptides
IL126714A (en) * 1997-02-28 2010-12-30 Enzo Therapeutics Inc Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
US20030170258A1 (en) * 2001-05-09 2003-09-11 Enzo Therapeutics, Inc. Novel processes implementing selective immune down regulation (SIDR)
US6919077B2 (en) * 2002-09-27 2005-07-19 Aids Research, Llc LFA-1 alpha subunit antibodies and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002869A (en) * 1987-11-02 1991-03-26 Dana-Farber Cancer Institute Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes

Also Published As

Publication number Publication date
DK1438970T3 (da) 2008-12-15
ES2314341T3 (es) 2009-03-16
EP0690725A1 (de) 1996-01-10
DE69435142D1 (de) 2008-10-30
ES2219647T3 (es) 2004-12-01
CA2156495A1 (en) 1994-09-29
EP1438970A3 (de) 2004-12-08
CA2156495C (en) 2008-11-18
EP0690725B1 (de) 2004-05-19
EP1438970A2 (de) 2004-07-21
HK1067958A1 (en) 2005-04-22
EP1438970B1 (de) 2008-09-17
CA2425086A1 (en) 2004-10-10
DE69433789D1 (de) 2004-06-24
PT1438970E (pt) 2008-12-26
PT690725E (pt) 2004-10-29
WO1994021295A1 (en) 1994-09-29
DE69433789T2 (de) 2005-06-23
ATE267019T1 (de) 2004-06-15
AU684074B2 (en) 1997-12-04
EP0690725A4 (de) 1997-09-03
US5424066A (en) 1995-06-13
AU6522194A (en) 1994-10-11

Similar Documents

Publication Publication Date Title
DE69434499D1 (de) Monoklonale Antikörper und Fv gegen das CD2 Antigen
EP1020522A4 (de) Natürlicher menschlicher antikörper
KR890002547A (ko) Hiv 감염의 치료 및 진단용 모노클로날항체 및 펩티드
ATE408418T1 (de) Methoden zur inhibition von hiv-assoziierten krankheiten mittels monoklonaler antikörper gegen sich selbstgerichtete zytotoxische t-zellen
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
BR0312808A (pt) Proteìna de fusão igg fc/hiv-gp120/c3d
ATE125870T1 (de) Hiv-spezifische monoklonale antikörper und hybridome zu ihrer herstellung.
ATE105938T1 (de) Monoklonale antikörper gegen spezifische antigene regionen des humanen immundefizienzvirus und methoden zur verwendung.
DE69213325D1 (de) Gegen das menschliche Immunschwäche-Virus gerichtetes Immunpräparat
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
ATE111485T1 (de) Peptidbehandlung von hartnäckigen infektionskrankheiten.
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
AU627540B2 (en) Drug for the treatment or prevention by passive immunization, of the hiv-infection and process for preparation thereof
DE69118702D1 (de) Neue verwendung eines monoklonalen antikörpers
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов
WO1999055162A8 (en) Method for the treatment of viral disease

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1438970

Country of ref document: EP